Hakutulokset - Dominik Heinzmann

  • Näytetään 1 - 5 yhteensä 5 tuloksesta
Tarkenna hakua
  1. 1
    Immunogenicity of Trastuzumab Intravenous and Subcutaneous Formulations in the Phase III Hannah Study

    Immunogenicity of Trastuzumab Intravenous and Subcutaneous Formulations in the Phase III Hannah Study Tekijä Roberto Hegg, Tadeusz Pieńkowski, S. Chen, Elżbieta Starosławska, S. Falcon, Н. В. Коваленко, N. Al-Sakaff, Dominik Heinzmann, Gerry Kolaitis, Gustavo Ismael

    Julkaistu 2012
    Hae kokoteksti
    Artigo
    Lisää suosikkeihin
    Tallennettuna:
  2. 2
    Population pharmacokinetic and exposure–response analysis for trastuzumab administered using a subcutaneous “manual syringe” injection or intravenously in women with HER2-positive early breast cancer

    Population pharmacokinetic and exposure–response analysis for trastuzumab administered using a subcutaneous “manual syringe” injection or intravenously in women with HER2-positive... Tekijä Angelica Quartino, Carina Hillenbach, Jing Li, Hanbin Li, Russell Wada, Jennifer Visich, Chunze Li, Dominik Heinzmann, Jin Y. Jin, Bert L. Lum

    Julkaistu 2015
    Hae kokoteksti Hae kokoteksti
    Artigo
    Lisää suosikkeihin
    Tallennettuna:
  3. 3
    Additional Safety Results of Hannah: A Phase III Randomised, Open-Label, International Study of the Subcutaneous Formulation of Trastuzumab (H) in HER2-Positive Early Breast Cancer Patients

    Additional Safety Results of Hannah: A Phase III Randomised, Open-Label, International Study of the Subcutaneous Formulation of Trastuzumab (H) in HER2-Positive Early Breast Cancer... Tekijä Christian Jackisch, Magdolna Dank, G. Frasci, K.H. Park, R.I. Lopez, Marilyn F.M. Johnston, Dominik Heinzmann, H. Wéber, Gustavo Ismael

    Julkaistu 2012
    Hae kokoteksti
    Artigo
    Lisää suosikkeihin
    Tallennettuna:
  4. 4
    Subcutaneous vs Intravenous Trastuzumab for Patients With ERBB2-Positive Early Breast Cancer

    Subcutaneous vs Intravenous Trastuzumab for Patients With ERBB2-Positive Early Breast Cancer Tekijä Christian Jackisch, Daniil Stroyakovskiy, Xavier Pivot, Jin Seok Ahn, Bohuslav Melichar, Shin‐Cheh Chen, Christoph Meyenberg, N. Al-Sakaff, Dominik Heinzmann, Roberto Hegg

    Julkaistu 2019
    Hae kokoteksti Hae kokoteksti
    Artigo
    Lisää suosikkeihin
    Tallennettuna:
  5. 5
    HannaH phase III randomised study: Association of total pathological complete response with event-free survival in HER2-positive early breast cancer treated with neoadjuvant–adjuvant trastuzumab after 2 years of treatment-free follow-up

    HannaH phase III randomised study: Association of total pathological complete response with event-free survival in HER2-positive early breast cancer treated with neoadjuvant–adjuva... Tekijä Christian Jackisch, Roberto Hegg, Daniil Stroyakovskiy, Jin‐Seok Ahn, Bohuslav Melichar, Shin‐Cheh Chen, Sung‐Bae Kim, Mikhail Lichinitser, Elżbieta Starosławska, G. Kunz, S. Falcon, Shou‐Tung Chen, A. Crepelle-Fléchais, Dominik Heinzmann, Mona Shing, Xavier Pivot

    Julkaistu 2016
    Hae kokoteksti
    Artigo
    Lisää suosikkeihin
    Tallennettuna:

Työkalut: